Dr. Stephen L. Graziano
Claim this profileState University of New York Upstate Medical University
Expert in Lung Cancer
Studies Non-Small Cell Lung Cancer
14 reported clinical trials
45 drugs studied
Area of expertise
1Lung Cancer
Global LeaderStage III
Stage IV
Stage II
2Non-Small Cell Lung Cancer
Stage III
Stage IV
Stage II
Affiliated Hospitals
Clinical Trials Stephen L. Graziano is currently running
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
More about Stephen L. Graziano
Clinical Trial Related5 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Stephen L. Graziano has experience with
- Carboplatin
- Pembrolizumab
- Paclitaxel
- Pemetrexed
- Durvalumab
- Biospecimen Collection
Breakdown of trials Stephen L. Graziano has run
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Anaplastic Large Cell Lymphoma
ALK Gene Rearrangement
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Stephen L. Graziano specialize in?
Stephen L. Graziano focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage III patients, or patients who are Stage IV.
Is Stephen L. Graziano currently recruiting for clinical trials?
Yes, Stephen L. Graziano is currently recruiting for 6 clinical trials in Syracuse New York. If you're interested in participating, you should apply.
Are there any treatments that Stephen L. Graziano has studied deeply?
Yes, Stephen L. Graziano has studied treatments such as Carboplatin, Pembrolizumab, Paclitaxel.
What is the best way to schedule an appointment with Stephen L. Graziano?
Apply for one of the trials that Stephen L. Graziano is conducting.
What is the office address of Stephen L. Graziano?
The office of Stephen L. Graziano is located at: State University of New York Upstate Medical University, Syracuse, New York 13210 United States. This is the address for their practice at the State University of New York Upstate Medical University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.